Learn More About UPTRAVI®


Details of the GRIPHON study, where the safety and efficacy of UPTRAVI® were investigated in a Phase 3 study to assess the long-term benefits for pulmonary arterial hypertension (PAH) patients.

Product Overview

A synopsis of the key benefits of UPTRAVI® in the treatment of PAH.

EM- 50402